Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-045913
Filing Date
2024-11-14
Accepted
2024-11-14 16:22:30
Documents
49
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 966615
2 ex31-1.htm EX-31.1 20172
3 ex31-2.htm EX-31.2 20372
4 ex32-1.htm EX-32.1 11105
  Complete submission text file 0001493152-24-045913.txt   4397399

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ptix-20240930.xsd EX-101.SCH 29053
6 XBRL CALCULATION FILE ptix-20240930_cal.xml EX-101.CAL 37976
7 XBRL DEFINITION FILE ptix-20240930_def.xml EX-101.DEF 162968
8 XBRL LABEL FILE ptix-20240930_lab.xml EX-101.LAB 283993
9 XBRL PRESENTATION FILE ptix-20240930_pre.xml EX-101.PRE 217336
52 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 640789
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12555 | Film No.: 241462831
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)